|[April 01, 2013]
Navidea Biopharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference
DUBLIN, Ohio --(Business Wire)--
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical
company focused on precision diagnostic radiopharmaceuticals, today
announced that Dr. Mark Pykett, Navidea's President and Chief Executive
Officer, will participate at the Future Leaders in the Biotech Industry
Conference on April 5, 2013 at the Millennium Broadway Hotel &
Conference Center, New York, NY. Dr. Pykett will provide an update of
the Company and its development programs at 9:30 AM EDT.
Investors and the public are invited to listen to a live webcast of Dr.
Pykett's presentation at http://www.media-server.com/m/p/exttmn6v.
Following the conference, the webcast will be archived for approximately
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is actively
developing four radiopharmaceutical agent platforms - Lymphoseek®,
NAV4694, NAV5001 and RIGScanTM - to help identify the sites
and pathways of undetected disease and enable better diagnostic
accuracy, clinical decision-making and, ultimately, patient care.
Navidea's strategy is to deliver superior growth and shareholder return
by bringing to market novel radiopharmaceutical agents and advancing the
Company's pipeline through selective acquisitions, global partnering and
commercialization efforts. For more information, please visit www.navidea.com.
[ InfoTech Spotlight's Homepage ]